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Although  understanding  the environmental  factors  that  contribute  to  breast  cancer  could  improve  dis-
ease  prevention,  standard  chemical  testing  protocols  do not  adequately  evaluate  chemicals’  effects  on
breast development.  Evidence  suggests:  (1)  mammary  gland  (MG)  development  is a complex  process  that
extends from  gestation  through  fetal  and  neonatal  growth,  puberty,  and  pregnancy;  (2)  altered  MG  devel-
opment  can  increase  the  risk  of  breast  cancer  and  other  adverse  outcomes;  and  (3)  chemical  exposures
during  susceptible  windows  of  development  may  alter  the  MG in  ways  that increase  risk  for  later  disease.ammary gland
evelopment
reast cancer
ndocrine disrupting compounds
oxicity testing
Together,  these  highlight  the  need  to better  understand  the  complex  relationship  between  exposure  to
endocrine  disrupting  compounds  (EDCs)  and  the  alterations  in  MG morphology  and  gene  expression
that  ultimately  increase  disease  risk.  Changing  guideline  toxicity  testing  studies  to  incorporate  perinatal
exposures  and MG whole  mounts  would  generate  critical  knowledge  about  the  effects  of  EDCs  on  the  MG
and could  ultimately  inform  disease  prevention.
ublis©  2014  The  Authors.  P
. Introduction
Breast cancer is the most common cancer in women worldwide
nd the second leading cause of cancer death in American women,
fter lung cancer [1,2]. The probability of a woman being diagnosed
ith breast cancer during her lifetime is one in eight [3]. While
nherited risk factors explain up to a third of breast cancer cases
4,5], the risk factors for the remaining majority of cases are not
ell understood. In addition to a steady increase in female breast
ancer, the incidence of male breast cancer has increased in the
ast few decades in the U.S. and internationally [6]. The correlation
f male and female incidence rates over time suggests that there
ay  be risk factors that are similar for both men  and women  [6,7].
xposure to chemicals in the environment and consumer products
s hypothesized to contribute to cancer risk [8–10], as well as to
ther breast health outcomes, such as impaired lactation [11] or
ale gynecomastia [12].
Despite emerging evidence that chemical exposure may  con-
ribute to breast cancer risk, most chemicals are not evaluated
or their potential impact on breast tissue, particularly dur-
ng vulnerable stages of development. Although understanding
he environmental factors that contribute to breast cancer has
∗ Corresponding author. Tel.: +1 15106434685; fax: +1 510 642 5815.
E-mail address: mschwarzman@berkeley.edu (M.  Schwarzman).
ttp://dx.doi.org/10.1016/j.reprotox.2014.07.077
890-6238/© 2014 The Authors. Published by Elsevier Inc. This is an open access article unhed  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
the potential to dramatically improve prevention of the disease,
standard chemical testing protocols do not adequately evaluate
chemicals’ effects on breast tissue. Most protocols lack an evalua-
tion of the effects of exposures during critical periods of mammary
gland (MG) development, as well as an assessment of functional
outcomes such as lactation impairment [13].
As a result, we have only limited evidence of how chemicals
such as endocrine disruptors (EDs) alter MG  development, and how
those effects contribute to adverse outcomes later in life. The evi-
dence that exists suggests three key points: (1) MG  development
is a complex process that extends from gestation through multi-
ple life stages; (2) altered MG development can increase the risk of
breast cancer, as well as other adverse outcomes; and (3) chemical
exposures during susceptible windows of development may alter
the MG  in ways that increase risk for later disease. Together, these
points highlight the need to better understand the complex rela-
tionship between environmental exposures and the alterations in
MG morphology and gene expression that ultimately increase the
risk of disease.
2. Mammary gland development is a complex process
extending from gestation through multiple life stagesNormal breast development in both humans and rodents
consists of a series of well-orchestrated events that are ﬁnely
regulated by a balance of hormones, growth factors, and
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tromal factors [14,15]. Growth depends on endocrine signaling
rom the hypothalamic–pituitary–gonadal axis, autocrine and
aracrine hormones, and growth factors from outside tissues.
rosstalk between the epithelium and surrounding stroma also
elps to balance proliferation and apoptosis during normal devel-
pmental remodeling of the MG [15,16].
The MG is distinct from other tissues in that it undergoes a sig-
iﬁcant portion of its development postnatally; in addition to the
etal/neonatal period, puberty and pregnancy are critical periods
f MG  development. In most mammals, MG  development begins
ith the formation of the mammary, or milk, line. This separates
nto individual placodes, each of which develops into a ductal tree
hat embeds in a fat pad to form the mammary bud [15,17,18]. Fac-
ors that interfere with signaling from the surrounding fat pad to
he mammary bud can potentially alter the timing of development
r formation of glandular structures [19,20].
Subsequent to the neonatal period there is little epithelial
rowth until puberty. During puberty, mammary growth is expo-
ential; this is a period of several weeks in rodents, or years in
irls, during which the fat pad rapidly ﬁlls with epithelial cells
o become the adult form of the gland. The epithelium develops
undles of ducts, which then form club-like structures, called ter-
inal end buds (TEB) in humans. Each TEB cleaves into alveolar
uds and sprouts into ductules. This structural unit, comprised of
he terminal duct and the ductules, is called the terminal ductal
obular units (TDLU) [21]. Rodents also form TEBs, which are the
tructures most functionally equivalent to TDLUs in humans. These
eardrop-shaped structures are the sites of future ductal branching
nd disappear as the gland differentiates [20].
In both humans and rodents, the key periods of develop-
ent in MG maturation are regulated by the activation (in
he fetal and neonatal periods) and later the reactivation (dur-
ng puberty) of the hypothalamic–pituitary–gonadal (HPG) and
ypothalamic–pituitary–adrenal (HPA) axes, which control the
elease of hormones [14,16,18].
The gland reaches a fairly static state from ﬁrst menstruation
ntil a pregnancy occurs. During pregnancy, the gland undergoes
nother period of rapid differentiation, involving branching and the
evelopment of lobulo-alveoli to prepare for lactation [19].
Male breast development also occurs in utero, but the androgen
urge halts further development immediately prior to birth. Expo-
ure to anti-androgens has been shown to lead to retained nipples
n male rats [22–24].
. Alterations to mammary gland development can
ncrease the risk of breast cancer and other adverse
utcomes
.1. Human evidence
The fetal origins of adult disease hypothesis propose that distur-
ances to the fetal environment have physiological and structural
onsequences with the potential to alter an individual’s disease
isk as an adult [25]. Human epidemiological studies provide sup-
ort for this hypothesis with respect to breast health outcomes,
s alterations to the ﬁnely regulated process of MG development
ave been shown to produce changes that affect women later in life.
or example, various birth parameters have been associated with
reast cancer risk. Birth weight [26], longer birth length [27], older
aternal and paternal age [28], and in utero exposure to synthetic
strogen and diethylstilbestrol (DES) [29] have all been associ-
ted with an increased risk of later breast cancer, while maternal
reeclampsia is associated with a lower risk [28,30]. Each of these
actors affects the earliest period of breast development that starts
efore birth.xicology 54 (2015) 148–155 149
The second period of breast development occurs during puberty.
Ionizing radiation has the greatest effect on later breast cancer
risk when exposure occurs before the age of 20 [31,32], suggest-
ing that the period from childhood through adolescence is another
signiﬁcant period of vulnerability for the human breast.
Pregnancy is a third period of breast development during which
external factors can alter disease susceptibility. Younger age at
ﬁrst birth, multiple gestation pregnancies (twins and greater),
preeclampsia, pre-pregnancy obesity, and gestational hyperten-
sion may  all lower maternal breast cancer risk (reviewed by
[33,34]), while increased placental weight [35], higher infant birth
weight [34], and DES exposure during pregnancy are associated
with increased risk of maternal breast cancer. One factor driving
these changes is total lifetime exposure to ovarian hormones. Lower
cumulative exposure to estrogen – such as with pre-eclampsia –
seems to protect against breast cancer [28]. Higher exposure to
progesterone may  increase risk of breast cancer, and affecting pro-
gesterone or progesterone receptor signaling pathways promotes
breast cancer progression [36,37].
The relationship between lifetime estrogen and progesterone
exposure and breast cancer risk provides a framework for under-
standing how chemicals that affect hormone homeostasis may  alter
breast development and ultimately cancer risk.
3.2. Rodent evidence
The rodent MG undergoes staged development analogous to
that observed in humans during gestation, puberty, and pregnancy.
Animal evidence further supports the hypothesis that there are
periods of vulnerability during breast development that inﬂuence
later life outcomes. A structure particularly important in rodent MG
development and carcinogen susceptibility is the TEB [20,38]. The
TEB has the greatest number of proliferating cells and the shortest
cell cycle of the structures in the developing MG.  Malignant tumors,
such as adenocarcinomas induced by certain carcinogens, are most
common in rodents following exposures that occur between days
40 and 46 of life (correlating with puberty in humans), the period of
development when TEBs are most actively differentiating into alve-
olar buds. Benign tumors, such as adenomas, ﬁbroadenomas, and
mammary cysts, are thought to arise from the more differentiated
alveolar buds [39].
Anything that changes the timing of mammary development
will affect the timing of the presence of TEBs, and therefore the
window of susceptibility to carcinogens. Earlier induction of MG
development in rodents leads to a greater number of TEBs com-
pared to terminal ducts and increased alveolar budding at the time
of weaning, followed by the development of more lobules than
in control animals [40,41]. On the other hand, late initiation of
mammary development causes decreased longitudinal growth of
the epithelium and fewer TEBs, and decreased alveolar budding at
weaning [42]. As development progresses, these glands may  have
more TEBs at puberty, because the pace of development is slower
[43]. It is hypothesized that factors that lengthen the period when
TEBs are present lengthen the period during which the MG  is sus-
ceptible to carcinogens.
3.3. Non-cancer effects
Altered MG development is also associated with non-cancer
effects such as lactation impairment and gynecomastia in both
rodents and humans. While it is recommended that infants are
breastfed exclusively for at least the ﬁrst six months of life [44],
several million mothers are unable to breastfeed or have signif-
icant difﬁculty breastfeeding each year [45]. Research in rodents
suggests that factors that interfere with MG growth and differenti-
ation can negatively affect both the gland’s ability to produce milk
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nd the milk composition [45,46]. Factors that accelerate MG  devel-
pment also make the gland less sensitive to ovarian and pituitary
ormones. Because effective lactation depends on these hormonal
ignals to stimulate the gland, a less responsive gland is less likely
o be capable of normal milk production [43].
Gynecomastia, or benign breast enlargement due to prolifera-
ion of the ductal epithelium [12], occurs in up to two-thirds of
ubertal boys [47]. It is hypothesized that the altered MG  devel-
pment that causes this condition arises due to an imbalance in
strogen and androgen [48,49].
. Exposure to chemicals during windows of susceptibility
an alter mammary gland structure and function,
ncreasing cancer risk
.1. The role of hormones and EDs
Many of the established risk factors for breast cancer are proxy
easures for changes in the hormonal environment [50–52]. For
xample, high birth weight, birth length, and placental weight
re associated with increased endogenous intrauterine estrogen
xposure [53,54], while pre-eclampsia is associated with increased
ndrogen levels [55]. Furthermore, DES, a synthetic estrogen pre-
cribed to prevent miscarriage from the 1940s through 1970s, has
een associated with breast cancer in women who were directly
xposed, as well as their daughters [29,56].
Levels of circulating estrogens and androgens are associated
ith breast cancer risk in both premenopausal and post-
enopausal women [57–59]. Breast cancer risk is elevated by
xtended exposure to high levels of endogenous hormones, which
an occur with obesity [60] or as a result of early age at menarche
r late age of ﬁrst pregnancy and menopause [61,62]. However, the
elationship between hormones and breast cancer is complicated
y the fact that breast cancer is a heterogeneous disease with at
east ﬁve molecular subtypes. The presence or absence of biolog-
cal markers, such as estrogen receptors (ER+/ER−), progesterone
eceptors (PR+/PR−), and human epidermal growth factor receptor
 (HER2+/HER2−),  serve as approximations of the molecular sub-
ypes [63]. The majority of information pertaining to hormonal risk
actors is speciﬁcally associated with the ER+/luminal A subtype.
he inﬂuence of hormones on ER− and triple negative (ER−, PR−,
nd HER2−) breast cancers are not as well characterized [57,64].
The endocrine system governs hormone production, and as
uch, plays a critical role in development and ongoing function
f multiple organ systems. Disruption of the endocrine system
s linked to multiple adverse outcomes, including metabolic dis-
urbances (e.g., obesity) [65], and alterations to lactation, breast
ensity [66], immune function [67,68], and the timing of puberty
69] and menopause [70]. An ED was originally deﬁned as “an
xogenous agent that interferes with the production, release,
ransport, metabolism, binding, action or elimination of natural
ormones in the body responsible for the maintenance of homeo-
tasis and the regulation of developmental processes” [71]. This
eﬁnition has been simpliﬁed by Zoeller et al. [72] to deﬁne an
D as “an exogenous chemical, or mixture of chemicals, that inter-
eres with any aspect of hormone action”. Compounds that have
strogen-like activity have been studied the most, yet chemicals
ith anti-estrogenic, androgenic, anti-androgenic, progesterone-
ike, and thyroid-like activity are also EDs [73].
.2. EDs as carcinogensDevelopmental exposure to EDs may  contribute indirectly to
 variety of adverse outcomes by altering MG  development in
ays that raise the risk of later disease. For example, chemicalxicology 54 (2015) 148–155
alterations to breast development in early life can increase the
tissue’s susceptibility to a subsequent carcinogenic exposure, a
so-called ‘second hit’ [43]. Carcinogen challenge models in experi-
mental animals have demonstrated these effects by using a known
chemical carcinogen following an early life chemical exposure to
show the increased rate of tumor formation in response to the
second exposure, relative to tumor incidence from the known
carcinogen alone [10]. This effect has been observed in rodents
with prenatal exposure to both estrogens and androgens [74–76].
Additionally, increased tumor number and accelerated tumor
development after carcinogen challenge have been observed fol-
lowing early life exposure to known EDs such as alcohol [77], dioxin
[78–80], bisphenol A (BPA) [81], and the phytoestrogen genistein
[82,83].
Research suggests that, in addition to increasing susceptibility
to a second hit by a chemical carcinogen, EDs may  have direct car-
cinogenic effects. For example, DES causes cervical, vaginal, uterine,
endometrial, and breast cancer via a combination of genotoxic,
estrogen-receptor-mediated, and epigenetic effects, independent
of subsequent carcinogen exposure [84]. A recent study demon-
strated that BPA caused a non-signiﬁcant increase in atypical
hyperplasia and adenocarcinoma of the MG at doses ranging from
0.25 to 250 micrograms/kg-day without later exposure to another
chemical carcinogen [85]. Taken together, these ﬁndings suggest
that in some cases EDs may  be complete carcinogens, not requiring
a second hit to cause cancer.
4.3. Rodent evidence
Rodent studies suggest that many mammary carcinogens also
alter MG development, often by accelerating or delaying devel-
opment and/or alter branching and epithelial structure (speciﬁc
chemicals reviewed in [10]). The effects of ED exposure are highly
dependent on the level and timing of exposure, and can even have
protective effects when exposure occurs at the right level and at
a particular developmental stage. EDs can stimulate growth, caus-
ing the MG  to mature with an increased ratio of fully differentiated
structures compared to immature or undifferentiated structures.
They can also reduce the ratio of proliferation to apoptosis in
the epithelium [43], reducing the risk for tumor formation. For
example, prenatal [78] and neonatal [79] dioxin exposure alters
rodent MG differentiation, increasing MG tumor development fol-
lowing treatment with dimethylbenz[a]anthracene (DMBA). In
contrast, dioxin exposure in long-term feeding studies decreases
spontaneous tumor development [86], and dioxin exposure dur-
ing pregnancy followed by treatment with DMBA four weeks later
delays tumor formation compared to controls [87]. Likewise, genis-
tein exposure during the peripubertal period decreases tumors
after a carcinogen challenge, while perinatal and lifelong exposure
appears to increase tumors in rats [88].
4.4. Human evidence
As with rodent studies, human studies demonstrate that out-
comes depend on the timing of exposure. Cohn et al. [89]
demonstrated that breast cancer is associated with DDT  exposure,
but only when exposure occurred before 14 years of age. This study
used blood samples obtained before DDT use was  banned to ﬁnd
that women  who  had high levels of serum DDT and were under 14
years old at time of exposure had a 5-fold increased risk of breast
cancer, while women who  were not exposed prior to 14 years of age
demonstrated no association. Because puberty is a period of rapid
development when the MG is particularly vulnerable to the effects
of chemical exposure, lengthening puberty extends this window of
susceptibility, thus increasing the possibility of ED exposure and
adverse outcomes. This is particularly concerning in light of the
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urrent shift toward earlier onset breast development in American
nd European girls, with girls now beginning breast development
thelarche) earlier and taking longer to reach full breast develop-
ent than in previous generations [90]. Endogenous hormones
lay a central role in the onset and regulation of puberty; estro-
en, the primary hormone in early breast development, promotes
rowth of the ducts, while progesterone promotes lobuloalveo-
ar development [73,91]. The physical changes seen in premature
helarche may  reﬂect the onset of pubertal maturation, or they
ay  reﬂect exposure to endogenous or exogenous hormones inde-
endent of the maturity stage of reproductive or adrenal systems
pseudo-puberty) [92]. In general, precocious puberty is associated
ith various adverse outcomes, including metabolic syndrome
nd polycystic ovarian syndrome, behavioral disorders, testicular
nd prostate cancer, and breast cancer in later life [92]. While
t is unknown if early thelarche is speciﬁcally associated with
ater breast disease, prolonging this sensitive developmental period
ncreases the potential that susceptible tissues will be exposed to
Ds or carcinogens [43].
.5. The question of dose
In addition to timing, effects of ED exposure depend on dose:
Ds can have complex dose response relationships – including
howing opposite effects at lower doses relative to higher doses
 which traditional toxicity testing methods are unable to detect
93]. Traditional toxicological studies typically use high doses to
etermine the maximum tolerated dose, lowest observed adverse
ffect level, and no observed adverse effect level, and extrapolate
o estimate effects at lower doses. Developing tissues in partic-
lar can be exquisitely sensitive to very low doses of EDs. BPA,
trazine [94], PFOA [95], and dioxin [80] have each been shown to
ffect the MG  at doses below those typically used in toxicological
tudies conducted for regulatory purposes. Exposure to concentra-
ions of BPA expected to produce circulating free BPA levels above
anomolar concentrations has been shown to alter MG  devel-
pment, gene and protein expression, histogenesis, or to induce
ammary hyperplasia in over a dozen studies (reviewed in [93]).
ammary epithelial cells exposed to nanomolar concentrations of
PA in culture demonstrate consistent effects [96].
Nonmonotonic dose-response (NMDR) curves are characterized
y a nonlinear relationship between dose and effect, with the slope
f the curve changing sign at some point in the range of doses
xamined. The effects of 17-estradiol [97,98] and DES [99] on the
G have displayed NMDR curves in mice. Observations of NMDR
urves in animal studies are particularly concerning because they
aise questions about whether effects observed at higher doses can
e extrapolated to lower doses more typical of human exposures,
nd raise concerns about missing important effects if testing is only
erformed at high doses.
.6. Non-cancer effects
Finally, EDs that alter MG development may  also affect the
tructure or function of the gland, causing changes such as
ynecomastia in men  or impaired lactation in women. In rodents,
igh doses of atrazine [100,101] and PFOA [95,102] have been
hown to severely inhibit mammary development, which then
ffects lactation and impairs the growth of developing off-
pring. While these high doses are rarely seen in humans, it is
ossible that ecological systems may  be exposed to levels that
lter animals’ development, impair lactation, and reduce offspring
urvival [43]. Other animal studies demonstrate that gestational
xposure to dioxin [45,103], BPA [46,104–107], genistein [108], and
iracin [109] not only alter mammary epithelial development, but
mpair lactation. It is possible that exposure to EDs contributes toxicology 54 (2015) 148–155 151
difﬁculty breastfeeding in women, but this outcome has not been
investigated.
A limited number of epidemiological studies of prepubertal
gynecomastia suggest an association with exposure to estrogenic or
androgenic substances in boys [110,111]. Case reports have linked
prepubertal gynecomastia to uses of tea tree oil and lavender oil,
both of which have weak estrogenic and antiandrogenic activity
[111]. While the mechanism is unclear, a variety of factors have
been associated with gynecomastia in humans and domestic ani-
mals, including estrogen, androgen deﬁciency, and exposure to
pyrethroid pesticides and some pharmaceuticals [48,112]. Since
the growth of MG ductal epithelium is stimulated by estrogens
and inhibited by androgens, EDs that alter the balance of estro-
gen or androgen stimulation may  contribute to this condition [48].
Additionally, gynecomastia is frequently associated with other con-
ditions that are related to hormonal imbalance. Vandenberg et al.
[12] demonstrated that MG development was altered in male mice
exposed to BPA during the perinatal period and studies of ethinyl
estradiol and genistein show that the male MG is a highly sensi-
tive marker of endocrine disruption [113], thus it appears that the
male breast is also sensitive to EDs during susceptible periods of
development.
5. Knowledge gaps
5.1. Understanding breast development
The three periods (i.e., fetal and neonatal growth, puberty, and
pregnancy) of rodent MG development are known to be analogous
to the periods of human breast development, however, research is
needed to further describe the timing and characteristics of breast
epithelial development and their relationship to adverse outcomes
such as increased susceptibility to carcinogens or diminished lacta-
tion in both humans and rodents. Additionally, there are large gaps
in our understanding of how MG development is regulated. It is
important to understand what speciﬁc regulatory factors and genes
are involved, as well as which receptor populations are present, and
when, in order to understand the mechanisms through which these
processes can be disrupted [55,73]. Elucidating the mechanisms
involved in breast development would improve our understand-
ing of breast cancer etiology, as well as non-cancer effects, such
lactation impairment and gynecomastia.
5.2. Understanding implications of altered development
Furthermore, while clear associations link various birth param-
eters to later life disease, the speciﬁc mechanisms through which
perturbations to breast development cause disease or dysfunc-
tion years later are unknown. Understanding these mechanisms
requires elucidation of the steps in mammary development and the
processes that are susceptible to alteration. For example, epidemi-
ologic evidence associates breast density with breast cancer risk.
Density can be inﬂuenced by factors that are also associated with
breast cancer risk (e.g., parity, number of births, and menopausal
status) [114]. The stromal matrix of the breast tissue actively par-
ticipates in the control of tumor growth [115–117] and may be
a crucial target for carcinogens [118], suggesting that altered tis-
sue architecture may  be at the core of carcinogenesis. Research is
needed to better understand the biological mechanisms respon-
sible for these links and how perturbing them inﬂuences risk of
cancer.5.3. Understanding EDs’ role in altered development and disease
Finally, animal studies demonstrate associations between
ED exposure, altered MG  development, and adverse outcomes.
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owever, the mechanisms by which EDs alter development and
roduce tumors are generally poorly understood. More informa-
ion is needed on the types of chemicals, the doses, and the timing
f exposure, as well as the ways that EDs act together, and the com-
lex interactions among genetics, stress, diet, and endogenous and
xogenous hormones.
Not only are there gaps in the knowledge concerning chemical
auses of breast cancer, but the effects of ED on breast milk produc-
ion and gynecomastia are largely unknown. Lactation impairment
s usually identiﬁed by decreased pup weight or survival in multi-
enerational rodent studies. However, these surrogate markers do
ot adequately detect functional outcomes because they are not
ensitive or speciﬁc for impaired lactation [13]. Additionally, multi-
enerational studies that can detect these effects are expensive and
are. An animal model has yet to be established to study gyneco-
astia, and there are very few studies investigating this condition.
. Recommendations: improving test protocols to
nvestigate how chemicals increase breast cancer risk and
lter mammary gland structure and function
.1. Include early developmental exposure in standard chemical
esting protocols
While many knowledge gaps persist, recent research sup-
orts theories of development and later life outcomes in which
nvironmental factors signiﬁcantly alter phenotype [52]. Human
pidemiologic studies are often unable to demonstrate associa-
ions between EDs and breast disease because exposures are not
ypically evaluated during critical periods of development. Longi-
udinal cohorts are of limited use in determining which early life
xposures or factors increase breast cancer risk due to the difﬁ-
ulties of accurately measuring exposures and the length of time
eeded to see effects in humans. For example, it took 60 years for
he effects of DES to appear [29]. As a result, the effects of EDs on
he MG cannot be truly understood without animal studies. Such
tudies can be designed so that each animal model provides infor-
ation concerning a particular aspect of human breast cancer and
s able to represent a speciﬁc subset of the varieties of human breast
isease [119].
In order to fully understand breast development and human
reast disease, a variety of laboratory animal models are needed.
aps in assessment of MG  effects in the rodent toxicology guide-
ines produced by U.S. EPA, OECD, and NTP indicate that a paradigm
hift is needed for these guideline studies to be able to detect critical
lterations to MG development [13]. While the two-year carcino-
enicity bioassays can assess MG  histopathology, not all guidelines
equire exposure to the developing rodent. Developmental toxicity
tudies, which could provide information on developmental effects
f EDs on the MG,  typically do not evaluate MG tissue. Similarly, the
tandard one- or two-generation reproduction study could provide
seful information on MG  developmental effects but is not rou-
inely used for this purpose.
The value of using the rat MG  to elucidate potential modes of
ction of known mammary carcinogens has been shown by sev-
ral investigators [119]. In most cases, these studies have been
onducted in specialized study designs with treatment periods
hat replicate the developmental processes known to be impor-
ant in the development of cancer. It is important to note that these
nquiries and discoveries have not been conducted within the con-
ext of the standard 2-year carcinogenicity bioassay, as the usual
rotocols do not begin dosing until early adulthood. Reasons for this
nclude (a) 2-year studies do not adequately assess changes that
ccur during especially sensitive life stages; (b) the studies are not
esigned to assess the consequences of early exposures that mayxicology 54 (2015) 148–155
change tissue susceptibility to later exposures; and (c) the tests
do not assess low-dose exposures to mixtures of chemicals that
better approximate actual human exposure to chemicals found in
the environment [120].
6.2. Evaluate MG development using whole mounts
Changing the two-year carcinogenesis study, developmental
toxicity study, and multigenerational toxicity study guidelines
would address these problems and improve our ability to under-
stand ED effects on the MG.  A protocol for evaluating whole mounts
of MGs  needs to be developed and validated that includes offspring
exposed during perinatal and pubertal stages and that ensures out-
comes are consistently reported among different laboratories. A
whole mount is a tissue preparation technique that enables eval-
uation of the entire unsectioned organ [121]. This technique can
identify morphological changes, as well as the temporal and spatial
progression of epithelial development because it enables visualiza-
tion of ductal branching [43]. Many laboratories use tissue sections,
which alone are insufﬁcient to detect developmental changes. Ide-
ally, data from histological analyses could be used in combination
with early life developmental end points seen in whole mounts
to assess the later life impacts of early developmental changes
[122]. Data generated from whole mounts could inform further
investigations into the lactational impairment in offspring or tumor
susceptibility using carcinogen-challenge protocols.
6.3. Other tools to improve testing
Another potential tool for evaluating chemical effects on the MG
is the use of the male rat, which has demonstrated more sensitiv-
ity than other ED endpoints in male or females. A range of studies
[113,123–125] indicate that the male rat MG is very sensitive to
estrogen and may  serve as a model for investigating the effects
of EDs, although relevance for the female MG would have to be
established [113,126].
Additional information can be gleaned from early biomarkers
associated with MG cancer that can be measured using MG tis-
sue blocks, serum samples, and other stored tissues. These include
changes in levels of hormones or hormone receptors, receptor sen-
sitivity, hyperplasia, gene markers, immunohistochemical markers,
MG-speciﬁc gene markers, and effects on stromal–epithelial inter-
actions [10]. Understanding these mechanisms would improve our
knowledge of the relationship between altered MG development
and later life outcomes.
Finally, toxicity information needs to be applicable to human-
relevant endpoints. This can be achieved by including more time
points during the investigation of MG developmental stages along
with blood collection for dosimetry to understand the transi-
tion from normal mammary tissue to tumor development [43,73].
Careful characterization of internal dose is needed in all (not
just guideline) studies [10,73]. Unlike laboratory animals, humans
are exposed to many different environmental chemicals simulta-
neously, thus an understanding of biologically relevant mixtures
that affect the mammary tissue is an important area of research.
7. Conclusion
Experimental evidence in rodent models and human epidemi-
ological studies provide preliminary evidence that some EDs can
affect normal MG  development and function, and so may  increase
breast cancer risk. These clues indicate that traditional toxicology
tests are likely missing many important effects on the MG.  Chem-
ical testing protocols should be standardized to require dosing
during critical periods of development, assessment of MG develop-
ment, structure, and function, and an assessment of the male MG.
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 greater understanding of these mechanisms will help to clarify
he risks of environmental exposures, provide evidence to reduce
xposure, and ultimately reduce the burden of disease.
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